U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07945821) titled 'A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors' on Nov. 13.
Brief Summary: The primary purpose of this study is to evaluate the safety and tolerability of tagmokitug in combination with other therapies.
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Solid Tumor
Intervention:
DRUG: Tagmokitug
Specified dose on specified days.
DRUG: Pasritamig
Specified dose on specified days.
Recruitment Status: RECRUITING
Sponsor: Coherus Oncology, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....